Fig. 1From: Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendmentsConsolidated Standards of Reporting Trials (CONSORT) guidelinesBack to article page